Market closedNon-fractional
Pliant Therapeutics/PLRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Pliant Therapeutics
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Ticker
PLRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
South San Francisco, United States
Employees
158
Website
pliantrx.com
PLRX Metrics
BasicAdvanced
$638M
Market cap
-
P/E ratio
-$2.86
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$638M
Beta
1.19
Financial strength
Current ratio
16.12
Quick ratio
15.949
Long term debt to equity
12.321
Total debt to equity
12.497
Interest coverage (TTM)
-138.79%
Management effectiveness
Return on assets (TTM)
-21.71%
Return on equity (TTM)
-34.17%
Valuation
Price to revenue (TTM)
2,549.398
Price to book
1.47
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-5.33
Growth
Revenue change (TTM)
-97.46%
Earnings per share change (TTM)
1.16%
3-year revenue growth
-74.55%
3-year earnings per share growth
4.10%
What the Analysts think about PLRX
Analyst Ratings
Majority rating from 14 analysts.
PLRX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$47M
14.11%
Profit margin
0.00%
NaN%
PLRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.70
-$0.69
-$0.78
-
Expected
-$0.71
-$0.78
-$0.81
-$0.77
-$0.85
Surprise
-1.87%
-9.68%
-15.22%
1.10%
-
PLRX News
AllArticlesVideos
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewsWire·3 weeks ago
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pliant Therapeutics stock?
Pliant Therapeutics (PLRX) has a market cap of $638M as of July 05, 2024.
What is the P/E ratio for Pliant Therapeutics stock?
The price to earnings (P/E) ratio for Pliant Therapeutics (PLRX) stock is 0 as of July 05, 2024.
Does Pliant Therapeutics stock pay dividends?
No, Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Pliant Therapeutics dividend payment date?
Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Pliant Therapeutics?
Pliant Therapeutics (PLRX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Pliant Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.